Justin Balster

Justin Balster serves as a key procurement professional within the National Cancer Institute, supporting the agency’s mission to accelerate breakthroughs in cancer research through strategic acquisition of high-value scientific and technical services. He manages a portfolio of complex contracts focused on advanced biomedical research support, including laboratory services, data analytics, and translational research infrastructure. His work directly enables the NCI’s pursuit of precision medicine and innovative therapeutic development by ensuring timely access to specialized scientific expertise and technical capabilities across the biomedical ecosystem. Balster maintains a consistent and long-standing relationship with Quality Biological, Inc., a trusted vendor providing critical reagents, biological materials, and specialized laboratory supplies essential to cancer research workflows. His contracting patterns reflect a preference for established, technically proficient contractors with proven capacity to deliver mission-critical scientific products under stringent quality and compliance standards. These partnerships are characterized by repeat engagements and performance-based contract structures that emphasize reliability, regulatory adherence, and scientific rigor. His procurement approach reflects a strong emphasis on open competition, with 100% of acquisitions conducted under non-set-aside authorities. There is no current reliance on 8(a), HUBZone, or SDVOSB set-asides, indicating a focus on technical capability and scientific suitability over socioeconomic categorization. This aligns with the NCI’s need for specialized, often niche, scientific services where vendor expertise outweighs socioeconomic preferences. The primary NAICS classification under his purview is 541990—All Other Professional, Scientific, and Technical Services—reflecting a focus on bespoke, non-standardized scientific support functions. He procures services ranging from molecular biology assay development and bioinformatics analysis to clinical trial support and regulatory compliance consulting, underscoring deep domain expertise in oncology research infrastructure and biomedical innovation ecosystems.